Abstract:Objective: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is of concern because of its propensity for rapid deterioration and high mortality. Its aetiology and mechanism are still unclear. The aims of this study were to clarify the pathophysiology differences between AE-IPF and stable IPF (S-IPF) by comparing the serum levels of various cytokines and chemokines in the two groups and to identify those involvement in the occurrence of acute exacerbation and associated with mortality. Methods: The study included 28 patients with AE-IPF, 32 patients with S-IPF, and 18 healthy control subjects. We measured the serum cytokine and chemokine levels in all cases by multiplex assay. Serum levels of cytokines and chemokines were compared between AE-IPF and S-IPF subjects. Logistic regression analysis was applied to identify the ability of these variables to predict acute exacerbation. Kaplan-Meier curves were used to analyse survival and Cox proportional hazard regression was used to identify predictors of survival. Results: Levels of several cytokines and chemokines were significantly higher in both patient groups with IPF (with the exception of interleukin-2 [IL-2], chemokine cc-motif ligand 3, and RANTES [regulation upon activation normal T-cell express sequence]) than in healthy controls. Serum IL-1 beta (p = 0.008) and interferon (IFN)-gamma (p = 0.007) levels tended to be higher in patients with AE-IPF than in those with S-IPF. The concentration of chemokine cc-motif ligand (CCL) 2 was significantly higher in bronchoalveolar lavage fluid than in serum (p = 0.001). Higher C-reactive protein, lactate dehydrogenase, percent forced vital capacity, percent diffusing capacity of the lung for carbon monoxide, and IFN-gamma values in the patients with IPF were correlated with acute exacerbation status, with respective odds ratios of 1.241 (p = 0.011), 1.050 (p = 0.004), 1.043 (p = 0.001), 0.927 (p = 0.014), and 0.929 (p = 0.020). Acute exacerbation status was associated with an increased risk of mortality (hazard ratio 0.107, 95% confidence interval 0.036-0.314; p < 0.001). Univariate Cox regression demonstrated an association of IFN-gamma, CCL2, C-X-C motif chemokine 10 (CXCL10) and sCD163 levels with an increased mortality risk (p = 0.015, p = 0.002, p = 0.001, and p = 0.030, respectively). Conclusions: Our data demonstrate that serum levels of some pro-inflammatory cytokines and macrophage chemokines are upregulated during acute exacerbations of IPF and that these exacerbations are associated with the serum IFN-gamma level. Chemokines and protein such as sCD163, CCL2, and CXCL10 are associated with activation of macrophages and may have a serious impact on overall survival in patients with IPF.

Late Breaking Abstract - Elevated Growth Differentiation Factor 15 in Serum Correlated with Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Serum Levels of IGFBP7 Are Elevated During Acute Exacerbation in COPD Patients.

Plasma Leptin is Elevated in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

Growth differentiation factor–15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis

Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis?

Growth Differentiation Factor-15 Is a Novel Biomarker Predicting Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Prognostic Value of IFN-γ, Scd163, CCL2 and CXCL10 Involved in Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension

Elevated Serum Human Epididymis Protein 4 is Associated with Disease Severity and Worse Survival in Idiopathic Pulmonary Fibrosis: a Cohort Study

Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism

Growth Differentiation Factor 15, a Marker of Lung Involvement in Systemic Sclerosis, Is Involved in Fibrosis Development but Is not Indispensable for Fibrosis Development

Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer

[Correlation Between Levels of Serum Growth Differentiation Factor-15 and Acute Coronary Syndrome].

[Different levels and clinical significance of growth differentiation factor-15 in patients with atrial fibrillation]

Associations of Serological Biomarkers of Sicam-1, IL-1β, MIF, and Su-Par with 3-Month Mortality in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.

GDF15 as a potential biomarker to distinguish fibrotic from non-fibrotic hypersensitivity pneumonitis

Blood eosinophilia: a predictive marker of acute exacerbations in fibrotic interstitial lung disease?

Transforming Growth Factor 15 Increased in Severe Aplastic Anemia Patients

GDF-15: A Potential Biomarker and Therapeutic Target in Systemic Lupus Erythematosus

GDF15 as a key disease target and biomarker: linking chronic lung diseases and ageing

Potential biomarkers for diagnosis and disease evaluation of idiopathic pulmonary fibrosis